Search PubMed⌕ Search

Biomedical subjects

A W Procter

Publications and source records attributed to A W Procter.

48 records · Page 3Linked to original sources
PubMed1988

Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer's disease.

Excitatory dicarboxylic amino acids previously have been ascribed several functions in the brain. Here their total concentration and proposed neurochemical markers of neurotransmitter function have been measured in brain from patients with Alzheimer's disease (AD) and controls. Specimens were obtained antemortem (biopsy) approximately 3 years after emergence of symptoms and promptly (less than 3 h) postmortem some 10 years after onset. Early in the disease a slight elevation in aspartic acid concentration of cerebral cortex was observed in the patients with AD. A reduction in glutamic acid concentration of a similar magnitude was found. It is argued that this, together with a decrease in CSF glutamine content and lack of change in the phosphate-activated brain glutaminase activity of tissue, reflects an early metabolic abnormality. Later in the disease evidence of glutamatergic neurone loss is provided by the finding that in many regions of the cerebral cortex the Na+-dependent uptake of D-[3H]aspartic acid was almost always lowest in AD subjects compared with control when assessed by a method designed to minimise artifacts and epiphenomena. Release of endogenous neurotransmitters from human brain tissue postmortem did not appear to have the characteristics of that from human tissue antemortem and rat brain.

Aged↗
PubMed1987

Mood and behaviour problems following the relocation of elderly patients with mental illness.

A prospective case-controlled study was carried out to evaluate the effect of an enforced move of elderly dementia sufferers from a large psychiatric hospital to smaller units in two general district hospitals. Changes in behaviour and nursing dependency, and mortality rate were used as outcome variables. The main finding was that a large proportion of the sample showed significant depressive behaviour following transfer. A significant degree of disturbed behaviour and disorientation remained 3 months after the move. There was some increase in the mortality rate of the group transferred relative to a comparison group but this did not reach statistical significance.

Affect↗
PubMed1986

Excitatory amino acid-releasing and cholinergic neurones in Alzheimer's disease.

Brains of normal controls and patients with primary degenerative dementia were investigated for choline acetyltransferase (ChAT) activity in the frontal, temporal and parietal cortex, hippocampus, amygdala and thalamus. A few patients with Alzheimer's disease were unusual as the cholinergic marker was unaffected, except in the amygdala. Other patients with dementia and undiagnosed neurodegenerative disorder had elevated cortical ChAT activity. The interpretations offered are: (a) the syndrome of dementia and Alzheimer pathologic change precedes significant loss of cortical cholinergic innervation; (b) denervation in dementia can occur early in olfactory areas, exemplified here by the amygdala; (c) dementia is associated with the loss of non-cholinergic structure. An indication of structures involved was given by loss of a marker of excitatory amino acid-releasing neurones.

Aged↗
PubMedDate not supplied

Pyramidal neuron loss and "glycine-site therapy": a need for an animal model and study in late-life depression.

Localization and other studies of glutamatergic receptors are hampered, in part, as pyramidal neurons in the neocortex cannot yet be selectively destroyed in laboratory animals. Demonstration of glutamatergic neuron dysfunction in Alzheimer's disease may allow verification of a technique suitable for the study of these cells in disorders without histopathological hallmarks. This includes Major Depressive Disorder in the elderly which has a poor prognosis.

Age Factors↗
PubMedDate not supplied

Brain membrane serine protease activity in human cortex compared with rat: implication for Alzheimer's disease.

Cerebral cortex from humans and rats was extracted sequentially with detergent-containing and low-ionic-strength buffers. The resulting pellet was extracted with detergent/high-ionic-strength buffer to yield a soluble enzyme preparation. This was incubated with substrate prepared from rat cerebral cortical membranes containing amyloid precursor protein-like immunoreactivity (APPLIR) of 116 kD approximate apparent molecular mass. The effectiveness of various enzyme preparations to degrade APPLIR was: routine-post-mortem (pm)-delay human samples > rat pup > short-pm-delay human samples >> adult rat. In incubations with human samples only a 100-kD product accumulated. The activity in human brain was inhibited by phenylmethylsulphonylfluoride, insensitive to Ca2+, correlated with pyramidal neurone numbers but not those of astrocytes and was not significantly higher in Alzheimer's disease compared with controls. These data are discussed in terms of other approaches for studying proteolytic activity to explain the deposition of beta-amyloid protein in this disease.

Aged↗
PubMedDate not supplied

Preliminary neurochemical findings in non-Alzheimer dementia due to lobar atrophy.

Non-Alzheimer's dementia due to lobar atrophy had choline acetyltransferase activities comparable with control rather than Alzheimer's disease values, based on 3 autopsy proven cases on Pick's disease and biopsies from 3 examples of dementia of frontal lobe type. Muscarinic cholinergic receptors were relatively spared only in Alzheimer's disease. Serotonin receptors were markedly reduced (based on Pick cases) whereas measures that reflected presynaptic serotonergic activity were either not affected or increased. Cerebrospinal fluid and brain tissue measurements suggested that inhibitory interneurones and dopamine release were relatively spared. There was no in vitro evidence of hypometabolism.

Atrophy↗